Journal article 246 views 38 downloads
Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
,
Maria Cristina Penaloza-Ramos,
Lola Adedokun,
Sarah Rees,
Mohamed Lockhat,
Lisa Spary,
Alan Watkins ,
Vincent Gnanapragasam,
Simon J. Crabb
Scientific Reports, Volume: 11, Issue: 1, Start page: 22151
Swansea University Authors:
Pete Arnold , Sarah Rees, Alan Watkins
-
PDF | Version of Record
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
Download (2.48MB)
DOI (Published version): 10.1038/s41598-021-01042-7
Abstract
This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patien...
| Published in: | Scientific Reports |
|---|---|
| ISSN: | 2045-2322 |
| Published: |
Springer Science and Business Media LLC
2021
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa58658 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patient record, termed non-metastatic castration-resistant PC (nmCRPC). Routinely collected administrative data in Wales were used to identify patients diagnosed with PC and nmCRPC from 2000–2015. Logrank tests and Cox proportional hazard models were used to compare time-to-events across subgroups defined by PSA doubling time and age. Of 38,021 patients identified with PC, 1,465 met nmCRPC criteria. PC incidence increased over the study period, while nmCRPC categorizations reduced. Median time from PC diagnosis to nmCRPC categorization was 3.07 years (95% confidence interval [CI] 2.91–3.26) and from nmCRPC categorization to metastases/death was 2.86 years (95% CI 2.67–3.09). Shorter PSA doubling time (≤ 10 months, versus > 10 months) was associated with reduced time to metastases or death (2.11 years [95% CI 1.92–2.30] versus 5.22 years [95% CI 4.87–5.51]). Age was not significantly associated with time to metastases/death. Our findings highlight key clinical characteristics and outcomes for patients with nmCRPC prior to the introduction of recently approved treatments. |
|---|---|
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
Janssen-Cilag Ltd |
| Issue: |
1 |
| Start Page: |
22151 |